- Bristol-Myers Squibb Co (NYSE: BMY) and its collaborating partner Acceleron Pharma Inc (NASDAQ: XLRN) have announced that Health Canada has approved Reblozyl (luspatercept for injection) to treat anemia in myelodysplastic syndromes (MDS) patients with ring sideroblasts.
- It is a low-risk subtype of blood cancer in which red blood cells contain a ring of excess iron.
- The approval is limited to those who require regular red blood cell transfusion and have failed an erythropoietin-based therapy.
- The treatment received FDA approval in April last year for the same indication. In Europe, the med was approved in June last year.
- Price Action: BMY shares are down 0.50% at $59.69, and XLRN shares are down 3.21% at $126.65 on last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
